CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

PURPOSE: The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic signific...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Chauhan, Lata, Shin, Miyoung, Wang, Yi-Cheng, Loken, Michael, Pollard, Jessica, Aplenc, Richard, Hirsch, Betsy A., Raimondi, Susana, Ries, Rhonda E., Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil, Lamba, Jatinder K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446480/
https://ncbi.nlm.nih.gov/pubmed/32914031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00387
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados